Navigation Links
New Drugs in Multinational Study Show Promise in Fighting,Drug-Resistant HIV

Phase III clinical trial provides hope that HIV patients can live longer lives

PASADENA, Calif., July 05, 2007 /PRNewswire/ -- A new investigational drug used in combination with a second newer agent has proven to be effective in fighting drug-resistant HIV, according to a Lancet article to be published in its July 7th special HIV/AIDS issue.

The multinational phase III clinical trial, which involved 18 nations and more than 30 centers in the United States, is the first trial to offer patients infected with resistant HIV the potential of receiving two investigational new drugs together to fight the disease. The two drugs, amongst the most powerful agents to fight the disease to date, are TMC125 (etravirine) and TMC114 (darunavir, also known as Prezista), both made by Tibotec (a Johnson & Johnson company), the sponsor of the ongoing trial. The data will be presented for the first time during the July 22nd-25th International AIDS Society conference in Sydney, Australia by the lead investigator in the trial, Dr. Adriano Lazzarin of Italy.

"This study is one of the most significant worldwide HIV/AIDS clinical trials in recent years. It showed that when the two drugs are used in combination, there is a good chance HIV can be very effectively controlled in patients who have advanced, multi-drug-resistant HIV," said William J. Towner, MD, Kaiser Permanente Southern California, a co-author of the Lancet article. Kaiser Permanente had the highest number of enrollees in the study from the United States.

Dr. Towner said that the ongoing 'DUET-2' trial -- large, randomized, and placebo controlled -- is the pivotal registration and efficacy trial for TMC125 (it is in a class of HIV drugs called non-nucleoside reverse transcriptase inhibitors [NNRTI]). The Lancet study found that at the 24th week, patients who received TMC125 in combination with TMC114 achieved superior virological suppression than t hose who received TMC114 alone. The results from the phase III clinical trial will be submitted to regulatory authorities, which must grant their approval before the new drug can be publicly available.

For the DUET trial, Kaiser Permanente enrolled the most patients of all the participating centers in the United States and was the third largest enroller in the world. Nationally, Kaiser Permanente is the second largest provider of HIV care, caring for more than 17,000 HIV infected patients. More than one million Americans are currently living with HIV, and the HIV/AIDS virus has killed more than 524,000 Americans to date.

Dr. Towner added that the trial is most uniquely significant because it utilized another novel HIV medication, TMC114 (in a class of HIV drugs called protease inhibitors; TMC114 was still an investigational agent when the trial started).

According to Dr. Towner, "Treating a resistant virus with two active agents has been a mantra in HIV care for quite some time. Adding only one active agent to a patient experiencing drug failure usually results in the rapid, predictable development of resistance to that agent. Very seldom do patients get the chance to receive two potent new investigational agents in one clinical trial. The DUET trials were one of the first to give the patients such a chance."

Dr. Towner is the Medical Director of Kaiser Permanente Southern California's HIV/AIDS Research Trials (HART) and the Kaiser Permanente Southern California Regional HIV/AIDS Physician Coordinator. The HART Program was founded in order to ensure that Kaiser Permanente HIV patients with advanced disease have access to the latest drugs.

Kaiser Permanente is America's leading integrated health plan. Founded in 1945, it is a not-for-profit, group practice program headquartered in Oakland, Calif. Kaiser Permanente serves more than 8.7 million members in nine states and the District of Columbia. Today it encompasses the not-for-profi t Kaiser Foundation Health Plan, Inc., Kaiser Foundation Hospitals and their subsidiaries, and the for-profit Permanente Medical Groups. Nationwide, Kaiser Permanente includes approximately 156,000 technical, administrative and clerical employees and caregivers, and 13,000 physicians representing all specialties. For more Kaiser Permanente news, visit the KP News Center at: http://xnet.kp.org/newscenter

CONTACT: Danielle Cass, +1-510-267-5354, or Calvin Naito, +1-626-405-5788,both of Kaiser Permanente

Web site: http://www.kaiserpermanente.org/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Monitoring Options Expand for Therapeutic Agents and Drugs of Abuse
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
4. Array BioPharma Reports New Clinical Data on Its Anti-Inflammatory Drugs
5. Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment
6. Major Manufacturer of Unapproved and Adulterated Drugs
7. Global Rabies Treatment May be Possible with NanoViricides Drugs
8. NanoViricides Drugs Found To Be Highly Effective Against Most Recent Strain of the H5N1 Avian Flu Virus
9. Research Supported by Samuel Waxman Cancer Research Foundation Discovers Mode of Action of Arsenic-Based Drugs in Destroying Cancer Cells
10. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
11. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... 2016 Automation is one of ... to the growing demands for productivity in speed, accuracy, ... systems are already adept of a wide range of ... manual labor. Instrumentation continues to evolve, and is poised ... a few years ago. Originally used mostly by the ...
(Date:4/28/2016)... April 28, 2016  While Abbott,s announced purchase ... company,s valve repair and stent business, healthcare research ... Abbott more firmly into patient monitoring.  Kalorama said ... growing device areas, with double-digit growth expected the ... Advanced Remote Patient Monitoring . Abbott ...
(Date:4/28/2016)... April 28, 2016  Marking its one year ... and ovarian cancer risk test, Color Genomics ... genes that highly impact the most common hereditary ... the Color Test analyzes hereditary cancer risks for ... uterine cancers. The Color Test is physician ordered ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... Create ... Abstract users can distort and manipulate three-dimensional shapes with ease all within ... ranks, point, lines, polygons, polygon texture animation, opacity texture animation, overall shape texture ...
(Date:4/30/2016)... , ... April 30, 2016 ... ... CBC News on April 4th, 2016 questioned the use of the HyProCure ... EOTTS-HyProCure as “a controversial procedure.” EOTTS-HyProCure is a minimally invasive procedure performed, ...
(Date:4/29/2016)... ... April 29, 2016 , ... In an article published April ... enthusiasm for Botox and lip injections, which she underwent in order to feel more ... Music and Arts Festival. The article explains that Ms. Mirmelli’s situation is not unique; ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, 2016 members of the ... signature of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. ... a 70% tax credit to individuals and corporations which donate directly to a “rural ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Coast Dental ... 16, 2016, at its new location in the Exchange Furniture Mall at 112 Vilseck ... for a 50-inch Samsung Smart TV. Plus attendees will have the opportunity to meet ...
Breaking Medicine News(10 mins):